Jerry Bhatt

Jerry Bhatt has been central to the development of IACS-010759, a potent and selective mitochondrial complex I inhibitor designed specifically for cancer therapy, which demonstrated significant anti-tumor activity in OXPHOS-dependent tumors including acute myeloid leukemia and brain tumors. His research identified that certain cancer subtypes, particularly AML stem cells and MYC-driven tumors, are critically dependent on oxidative phosphorylation and vulnerable to complex I inhibition. He established pharmacodynamic biomarkers for OXPHOS inhibition in clinical trials and defined the metabolic adaptations that contribute to IACS-010759 resistance. His translational work has advanced the clinical development of mitochondrial-targeted cancer therapies.